Overexpression of collagen triple helix repeat containing 1 (CTHRC1) is associated with tumour aggressiveness and poor prognosis in human non-small cell lung cancer

Oncotarget

Volumn 5, Issue 19, 2014, Pages 9410-9424

  Ke, Zunfu ^a   He, Weiling ^a   Lai, Yuanhui ^a   Guo, Xuefeng ^b   Chen, Sharon ^c   Li, Shuhua ^a   Wang, Yuefeng ^a   Wang, Liantang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CTHRC1 non small cell lung cancer catenin metastasis prognosis

Indexed keywords

BETA CATENIN; COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1 PROTEIN; GLYCOGEN SYNTHASE KINASE 3; MESSENGER RNA; ONCOPROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WNT PROTEIN; CTHRC1 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3 BETA; SCLEROPROTEIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CORRELATIONAL STUDY; CTHRC1 GENE; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR INVASION; UPREGULATION; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

BETA CATENIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84910037773     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2421     Document Type: Article

References (38)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29.
2. She J, Yang P, Hong Q and Bai C. Lung cancer in China: challenges and interventions. Chest. 2013; 143(4):1117-1126.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4): 225-249.
4. Reck M. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Ann Oncol. 2012; 23(Suppl 8):viii28-34.
5. Miller YE. Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol. 2005; 33(3):216-223.
6. Hood JD and Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002; 2(2):91-100.
7. Nobes CD and Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell. 1995; 81(1):53-62.
8. Leber MF and Efferth T. Molecular principles of cancer invasion and metastasis (review). Int J Oncol. 2009; 34(4):881-895.
9. Gupta GP and Massagué J. Cancer metastasis: building a framework. Cell. 2006; 127(4):679-695.
10. Vogelstein B and Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004; 10(8):789-799.
11. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P and Matrisian LM. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene. 1999; 18(18):2883-2891.
12. Marchenko ND, Marchenko GN, Weinreb RN, Lindsey JD, Kyshtoobayeva A, Crawford HC and Strongin AY. Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int J Biochem Cell Biol. 2004; 36(5): 942-956.
13. Pacheco-Pinedo EC, Durham AC, Stewart KM, Goss AM, Lu MM, Demayo FJ and Morrisey EE. Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest. 2011; 121(5):1935-1945.
14. Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukyanov S, Lukyanov K, GurskayaN, Sverdlov ED and Siebert PD. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci U S A. 1996; 93(12): 6025-6030.
15. Durmus T, LeClair RJ, Park KS, Terzic A, Yoon JK and Lindner V. Expression analysis of the novel gene collagen triple helix repeat containing-1 (Cthrc1). Gene Expr Pattern. 2006; 6(8):935-940.
16. LeClair R and Lindner V. The role of collagen triple helix repeat containing 1 in injured arteries, collagen expression, and transforming growth factor beta signaling. Trends Cardiovasc Med. 2007; 17(6):202-205.
17. Tang L, Dai DL, Su M, Martinka M, Li G and Zhou Y. Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res. 2006; 12(12):3716-3722.
18. Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, Ehrmann J, Klein J, Fridman E, Skarda J, Srovnal J, Hajduch M, Murray P and Kolar Z. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer. 2007; 7:55.
19. Ip W, Wellman-Labadie O, Tang L, Su M, Yu R, Dutz J, Wang Y, Huang S, Zhang X, Huang C and Zhou Y. Collagen triple helix repeat containing 1 promotes melanoma cell adhe-sion and survival. J Cutan Med Surg. 2011; 15(2):103-110.
20. Yamamoto S, Nishimura O, Misaki K, Nishita M, Minami Y, Yonemura S, Tarui H and Sasaki H. Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex. Dev Cell. 2008; 15(1):23-36.
21. Pyagay P, Heroult M, Wang Q, Lehnert W, Belden J, Liaw L, Friesel RE and Lindner V. Collagen triple helix repeat containing 1, a novel secreted protein in injuredand diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res. 2005; 96(2):261-268.
22. Kharaishvili G, Cizkova M, Bouchalova K, Mgebrishvili G, Kolar Z and Bouchal J. Collagen triple helix repeat containing 1 protein, periostin and versican in primary and metastatic breast cancer: an immunohistochemical study. JClin Pathol. 2011; 64(11):977-982.
23. Logan CY and Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004; 20:781-810.
24. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, ChenK, Walker J, McDonald S, Bose R, Ornitz D, XiongD, You M, Dooling DJ, Watson M, Mardis ER and Wilson RK. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012; 150(6):1121-1134.
25. Kim HC, Kim YS, Oh HW, Kim K, Oh SS, Kim JT, KimBY, Lee SJ, Choe YK, Kim DH, Kim SH, Chae SW, Kim KD and Lee HG. Collagen triple helix repeat containing 1 (CTHRC1) acts via ERK-dependent induction of MMP9 to promote invasion of colorectal cancer cells. Oncotarget. 2014; 5(2):519-529.
26. Ma MZ, Zhuang C, Yang XM, Zhang ZZ, Ma H, Zhang WM, You H, Qin W, Gu J, Yang S, Cao H and Zhang ZG. CTHRC1 acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-Rho signaling. Neoplasia. 2014; 16(3): 265-278.e1-13.
27. Chen YL, Wang TH, Hsu HC, Yuan RH and Jeng YM. Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis. PLoS One. 2013; 8(7):e70324.
28. Park EH, Kim S, Jo JY, Kim SJ, Hwang Y, Kim JM, Song SY, Lee DK and Koh SS. Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells. Carcinogenesis. 2013; 34(3):694-702.
29. Karner C, Wharton KA Jr and Carroll TJ. Planar cell polarity and vertebrate organogenesis. Semin Cell Dev Biol. 2006; 17(2):194-203.
30. Moon RT, Bowerman B, Boutros M and Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science. 2002; 296(5573):1644-1646.
31. Chien AJ, Conrad WH and Moon RT. A Wnt survival guide: from flies to human disease. J Invest Dermatol. 2009; 129(7):1614-1627.
32. Giles RH, van Es JH and Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003; 1653(1):1-24.
33. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X and He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002; 108(6):837-847.
34. Embi N, Rylatt DB and Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem. 1980; 107(2):519-527.
35. Jope RS and Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004; 29(2):95-102.
36. Doble BW and Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003; 116(Pt 7): 1175-1186.
37. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990; 9(8):2431-2438.
38. Ke Z, Zhang X, Ma L and Wang L. Expression of DPC4/Smad4 in non-small-cell lung carcinoma and its relationship with angiogenesis. Neoplasma. 2008; 55(4):323-329.